Webinar Alert! Building Robust Potency Assays with In-Cell Western Assay Protein Expression Readouts Register Today!

Quantitative Proteomics for Evaluating Off-Target Effects in Gene Editing Therapies (CRISPR-Cas9)

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Quantitative Proteomics for Evaluating Off-Target Effects in Gene Editing Therapies (CRISPR-Cas9)

Quantitative Proteomics for CRISPR-Cas9 Off-Target Effect Assessment

CELL & GENE | RNA | BIOLOGICS

    What is the primary advantage of using mass spectrometry-based proteomics for off-target analysis over genomic methods?

    Proteomics provides direct, empirical evidence of functional changes at the protein level. While genomic methods are excellent for identifying potential DNA edits, quantitative proteomics measures the actual downstream consequences, confirming whether a predicted off-target cut results in an aberrant change in protein expression that could impact safety and efficacy.

    How does your quantitative proteomics workflow differentiate on-target protein changes from genuine off-target effects?

    Our platform uses comparative quantitative techniques, such as isobaric tagging (TMT) or stable isotope labeling, to precisely measure protein abundance between treated and control groups. Rigorous bioinformatic pipelines then apply statistical models to filter for high-confidence, non-target protein expression changes that are distinct from the intended therapeutic effect and biological noise.

    What sample types are compatible with this service?

    We routinely process a wide range of GxP-compliant sample matrices, including in vitro cell models, primary cells, and in vivo tissue samples from key organ systems relevant to your program’s non-target tissue biodistribution profile.

    What is the typical turnaround time for a comprehensive off-target proteomics study?

    Timelines are project-dependent and scaled to study complexity. However, standard discovery-phase projects typically move from sample receipt to a full data package and interpretation report in several weeks, aligning with accelerated development schedules.

Mass spectrometry-based quantitative proteomics provides the most direct functional evidence of off-target effects from CRISPR-Cas9 and other gene editing modalities. This analytical approach moves beyond predictive in silico algorithms and genomic sequencing to measure actual changes in the proteome. Integrating this empirical protein-level data is a necessary component for building a robust IND-enabling safety package for novel therapeutics.

Characterizing the Proteomic Impact of Gene Editing

Gene editing therapies require definitive, empirical evidence of on-target specificity to satisfy regulatory expectations. While genomic sequencing methods effectively identify potential off-target DNA cleavage sites, they do not reveal the functional consequences of these events. A silent genomic alteration is biologically distinct from one that aberrantly alters protein expression.

Quantitative proteomics closes this information gap. By precisely measuring the entire expressed proteome, we can identify unintended changes in protein abundance that result from off-target editing. This analysis provides a clear, functional readout of specificity, allowing program leaders to de-risk development candidates with high confidence before committing to extensive in vivo studies.

A close-up, blue-toned image of scientific glassware, featuring vials placed in a dish filled with clear, spherical beads, suggesting a laboratory or research setting.

A scientist in a modern lab analyzes colorful DNA sequencing data on a tablet.

The Infrastructure for Advanced Therapeutic Assessment

The logistical and technical infrastructure required to support these advanced analytical methods is substantial. Executing GxP-compliant proteomics at scale demands specialized instrumentation and expertise.

A Quantitative Approach to Safety and Specificity

Our workflow is designed to deliver unambiguous, actionable data for safety assessment. This process is conducted within our >100,000 sq ft facility, ensuring capacity for complex, parallel projects.

  • Sample Preparation: We utilize optimized protocols for protein extraction and digestion from diverse biological matrices to ensure maximum proteome coverage.

  • High-Resolution Mass Spectrometry: Samples are analyzed using advanced LC-MS/MS platforms to generate high-resolution spectral data, enabling the identification and quantification of thousands of proteins.

  • Bioinformatic Analysis: A proprietary data analysis pipeline identifies statistically significant differences in protein abundance between test and control articles, mapping them to biological pathways.

A close-up of a multi-channel pipette dispensing liquid into a microplate in a laboratory setting, with a blue color overlay.

A close-up, detailed shot of a Sartorius Stedim Biotech BIOSTAT STR® single-use bioreactor in a laboratory setting.

De-Risking Novel Delivery Systems

The efficacy of gene editing tools is directly linked to the efficiency of their delivery systems. As new non-viral vectors are developed, such as the branched ionizable lipids for LNP delivery of CRISPR-Cas9 ribonucleoprotein complexes discussed in recent literature (PMID: 39856035), the analytical burden shifts. Improving delivery efficiency necessitates an equally sophisticated method for confirming that enhanced potency does not come at the cost of reduced specificity. Proteomics provides this definitive safety check for next-generation delivery platforms.

From Raw Data to IND-Enabling Insights

Our team translates complex proteomics datasets into clear, IND-enabling reports. This focus on regulatory alignment has supported an average 18-24 month IND timeline for our partners. While the Franklin Biolabs brand launched in 2024, our core scientific leadership and quality systems have contributed to a 100% IND-enabling package success rate since 2019. The table below outlines the complementary roles of proteomic and genomic analyses.

Feature Quantitative Proteomics (LC-MS/MS) Next-Generation Sequencing (NGS)
Endpoint Measured Actual protein expression changes Potential DNA sequence alterations
Biological Relevance Direct functional impact Inferred functional impact
Sensitivity Detects subtle proteome shifts High sensitivity for genomic edits
Primary Application Functional safety assessment Specificity & guide RNA optimization

A scientist in a lab coat and gloves looks through a microscope in a laboratory setting, with a blue color overlay.

Commitment to Ethical Research Standards

Our programs strictly adhere to the 3Rs principles (Replacement, Reduction, and Refinement) and are fully compliant with AAALAC and USDA standards.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities